Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. (APRE) Q1 2026 Earnings

APRE·Reported May 13, 2026·Before market open

Aprea Therapeutics, Inc. reported Q1 2026 revenue of $281.0K (+73.0% YoY). Diluted EPS came in at $-0.22 (+66.7% YoY), beat the $-0.23 consensus by $0.01.

Revenue
$281.0K
Diluted EPS
$-0.22beat by $0.01
Consensus: $-0.23
SEC

SEC Filings

Earnings release8-K · 0001104659-26-059734
Quarterly report10-Q · 0001104659-26-059743

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Aprea Therapeutics, Inc.'s Q1 2026 earnings report.

Aprea Therapeutics, Inc. (APRE) reported Q1 2026 earnings on May 13, 2026 before market open.

Aprea Therapeutics, Inc. reported revenue of $281.0K and diluted EPS of $-0.22 for Q1 2026.

EPS beat the consensus estimate of $-0.23 by $0.01.

Compared to the same quarter a year prior, revenue grew 73.0% from $162.5K a year earlier and diluted EPS grew 66.7% from $-0.66.

You can read the 8-K earnings release (0001104659-26-059734) and the 10-Q periodic report (0001104659-26-059743) directly on SEC EDGAR. The filing index links above go to sec.gov.